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Introduction
Patients with typical Chronic Inflammatory Demy-
elinating Polyneuropathy (CIDP) experience motor and 
sensory deficits that progress insidiously over a course of 
at least eight weeks, with diminished or absent reflexes.1,2 
There have been several revisions to the diagnostic criteria 
for CIDP over the years to aid clinicians in making this diag-
nosis, with variable sensitivity and specificity.3-6 Given this, 
clinicians need to be aware of red flags that would lead one 
to consider an alternative diagnosis, such as Transthyretin 
Familial Amyloid Polyneuropathy (TTR-FAP).7
Systemic amyloidosis is caused by pathologic deposi-
tion of misfolded proteins, which leads to widespread tissue 
and organ damage. Amyloidosis can be genetic, acquired 
by primary hematological disorder, reactive, or related to 
natural aging.8 FAP is the most common hereditary form of 
systemic amyloidosis, which is caused by mutations in TTR, 
and less commonly apolipoprotein A1, and gelsolin. TTR-
FAP is inherited in an autosomal dominant fashion, but has 
variable penetrance.9 Yet in late-onset cases, only one-third 
have a positive family history.10 Transthyretin is primar-
ily produced in the liver, but a small amount is made in the 
choroid plexus and retina. It functions to transport thyrox-
ine and retinol binding protein, which incidentally is how 
the name transthyretin was derived. All known mutations 
are missense point mutations, that lead to the destabiliza-
tion of the TTR tetramer and deposition of insoluble TTR 
oligomeric amyloid protein aggregates. This deposition can 
cause multiorgan dysfunction, affecting peripheral nerves, 
heart, liver, eyes, and leptomeninges. Phenotypic variation 
exists, however TTR-FAP classically presents as a length 
dependent neuropathy, predominantly small fiber sensory 
in early-onset cases, in patients prior to age 50. This group 
also tend to have prominent autonomic and cardiac dys-
function. Late-onset cases are more difficult to identify due 
to less prominent autonomic symptoms and in twenty per-
cent of cases, a weakness pattern mimicking CIDP.11
Case Report
A 75-year-old right-handed female presented with 
a 5-year history of progressive extremity numbness and 
weakness. She first noticed numbness and tingling in her 
fingers and toes, that progressed to her mid arms and thighs. 
She also noticed imbalance and difficulty climbing stairs 
that progressed to weakness in her arms. She also reported 
unintentional weight loss, orthostasis, and difficulty empty-
ing her bladder. She was previously diagnosed with CIDP, 
but failed to respond to corticosteroids or IVIG, and was re-
cently placed on azathioprine at an outside clinic. There was 
no family history of neuropathy. Neurologic exam revealed 
symmetric moderate proximal and distal extremity weak-
ness, with sparing of cranial and neck musculature. There 
was atrophy of distal extremities. On sensory examination, 
pinprick was diminished to elbows and knees, as well as 
impaired vibratory sense. Romberg was positive. Reflexes 
were absent to reduced throughout. Gait was wide-based 
and steppage. 
Electrophysiological Findings
Electrodiagnostic testing showed a moderate mostly 
symmetric axonal and demyelinating sensorimotor periph-
eral polyneuropathy (Table 1). We identified > 30% tempo-
ral dispersion at left medial nerve (distal and proximal du-
ration 5.4 ms and 7.1 ms, respectively), and increased distal 
CMAP duration of left ulnar nerve at the wrist (data not 
shown in the Table) was 7.3 ms.  This value was considered 
prolonged per EFNS/PNS 2010 Criteria since it was ≥ 6.7 
ms.  In conjunction with the clinical presentation, fulfilled 
the criteria for definite CIDP based on EFNS 2010 criteria. 
Additional Investigation
Cerebral spinal fluid protein was 73 mg/dL. Given re-
fractoriness to two of the first line therapies for CIDP and 
due to the presence of mild autonomic symptoms, we evalu-
ated the patient for CIDP mimics and suspected an alter-
nate diagnosis. The patient underwent a sural nerve and 
vastus lateralis muscle biopsy. The nerve biopsy revealed 
severe loss of large caliber myelinated never fibers and am-
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Table 1: Electrophysiologic Findings. Sensory nerve, motor nerve conduction studies, and need electromyography show 
asymmetric axonal demyelinating moderate peripheral polyneuropathy. There is left median nerve temporal dispersion 
along with increased distal CMAP duration of left ulnar nerve that fulfills EFNS 2010 criteria for CIDP.  Rec: recruitment, 
mld: mild, mod: moderate, sev: severe, dec: decreased, ULN: Upper limit of normal, LLN: Lower limit of normal.
Sensory nerve conduction
Peak Latency [ms] 
(ULN) Amplitude [µV] (LLN)
Median.R to Index 6.0 (3.7) 9 (15.0)
Ulnar.R to Digit V 2.9 (3.1) 6 (5.0)
Radial.R to Anat Snuff Box NR (2.8) NR (10.0)
Sural.R to Ankle 4.5 (4.5) 2 (3.0)
Sural.L to Ankle NR (4.5) NR (3.0)
Motor nerve conduction
Onset Latency [ms] 
(ULN) Amplitude [mV] (LLN)
Conduction Velocity 
[m/s] (LLN)
Median.R to APB. Wrist 
Elbow
4.9 (4.5) 
9.9
2.8 (4.5) 
2.7
41 (49)
Ulnar.R to ADM Wrist 
B. Elbow 
A. Elbow
3.4 (3.6) 
6.5 
8.7
2.2 (5.0) 
2.6 
2.2
50 (50)
48
Peroneal.R to EDB. Ankle 
B. Fib Head
A. Fib Head
4.3 (6.6) 
12.0 
15.0
0.4 (2.0) 
0.3 
0.3
36 (41)
40
Peroneal.R to TA. B. Fib Head 
A. Fib Head
3.2 (4.0) 
6.3
1.5 (3.0) 
1.3
37 (40)
Tibial.R to AH. Ankle 
Pop. Fossa
4.7 (6.0) 
13.4 
2.2 (4.0) 
2.0 
43 (57)
Median.L to APB. Wrist  
Elbow
4.4 (4.5) 
8.6
4.8 (4.5) 
3.4
50 (49)
Ulnar.L to ADM. Wrist 
B. Elbow 
A. Elbow
3.1 (3.6) 
6.6 
8.6
4.4 (5.0) 
4.3 
3.9
 
52 (50) 
50
Muscle Act Fibs PSW Fasc Poly Amp Dur Rec
Tibialis anterior. R - 2+ 2+ - + + + -
Gastroc Med H. R - 2+ 2+ - + + + mod dec
Vastus lateralis. R - 1+ 1+ - - + + sev dec
Gluteus medius. R - 3+ 3+ - + - - mld dec
Lumbar paraspinal; low. R - 2+ 2+ -
1st dorsal interossei. R - 3+ 3+ - + - - mod dec
Biceps brachii. R - 3+ 3+ - + - + mod dec
Deltoid. R - 3+ 3+ - + + + mod dec
Extensor indicis proprius. R - 2+ 2+ - + + + mod dec
Triceps brachii. R - 1+ 1+ Few + + + mld dec
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yloid deposition within the endoneurium by Thioflavin-S 
and Congo Red stains (not shown). The muscle biopsy iden-
tified clusters of atrophic myofibers. It also revealed amy-
loid deposition by Thioflavin S and Congo Red stains, and 
established this as transthyretin via immunohistochemical 
reaction (Figure 1). Genetic testing for TTR sequence con-
firmed a point mutation of A to G at position 3861 of allele 
1. This mutation led to missense mutation of threonine to 
alanine at codon position 60, a known pathologic mutation.
To investigate for systemic involvement, an echocar-
diogram was preformed and demonstrated speckled myo-
cardium, valvular thickening, and moderate concentric left 
ventricular hypertrophy consistent with amyloid deposi-
tion. She was evaluated by our liver transplantation team, 
but given her widespread disease involvement and age, she 
was not a candidate for liver transplant. She was started on 
diflunisal since at the time of her diagnosis, as neither an-
tisense oligonucleotide therapy nor small interfering RNA 
was available. Genetic counselling was provided and she 
was lost to follow.
Discussion
This case highlights the importance of re-evaluation in 
patients who otherwise fit the diagnostic criteria for CIDP 
and are either refractory to first line therapies or have un-
usual manifestations (family history, dysautonomia, etc.). 
Additionally, this case displays some common clinical fea-
tures and pitfalls of patients with late-onset TTR-FAP. 
TTR-FAP is a heterogenous disorder, with wide variation 
in age of onset, neurologic and systemic manifestations. In 
late-onset cases, the majority are without a positive family 
history. Therefore, a clinician needs a high index of suspi-
cion, otherwise there can be significant delay in diagnosis. 
An accurate and timely diagnosis is particularly important 
Figure 1. Vastus lateralis muscle biopsy sections. Small amyloid depositions are shown within blood vessel wall (A) and along 
muscle fiber surface (B) by Congo red stain under polarized light (arrow). Arrowheads in C and D show transthyretin anti-
body reaction, which identifies amyloid along muscle fiber surface (C) and within muscle cells (D).
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since several treatment options are currently available for 
TTR-FAP.12-15 In a study of patients presenting with sporad-
ic onset in non-endemic areas, the mean time to diagnosis 
was four years.11 In patients with autonomic dysfunction, 
cardiomyopathy, and lack of response to adequate therapy 
for CIDP, the diagnosis of TTR-FAP should be considered 
as to not delay clinical diagnosis, expose patient to unnec-
essary therapies, nor delay effective novel therapies. Recent 
expert consensus recommendations to improve diagnosis 
of TTR amyloidosis with polyneuropathy were published 
to avoid confusion with CIDP, idiopathic axonal polyneu-
ropathy, lumbar spinal stenosis, and, more rarely, diabetic 
neuropathy and AL amyloidosis.16 The challenge in recogni-
tion of TTR amyloidosis is more prominent in non-endemic 
areas, namely outside Portugal, Japan, Sweden, and Brazil. 
A high index of suspicion is required.
Currently used diagnostic criteria for CIDP are highly 
sensitive with 80 to 85% specificity. The PREDICT study 
was a multicenter randomized controlled trial of 6 monthly 
pulses of dexamethasone versus 8 months of daily prednis-
olone.17 In this study, 10/39 (26%) were cured (>5 years off 
treatment) or in remission according to the CIDP Disease 
Activity Status scale after 1 or 2 courses of dexamethasone 
or prednisolone. Despite these CIDP patients being diag-
nosed by experts and using specified criteria, alternative 
diagnosis was found 7 out of 12 (58%) cases who did not re-
spond to any therapy included 3 having hereditary neuropa-
thy, 2 malignancy (lymphoma, plasmacytoma),1 TTR-FAP 
and 1 IgM paraprotein. This suggests a specificity of the 
ENMC diagnostic criteria for CIDP of 83%.17,18 In another 
study, 44% of patients misdiagnosed as CIDP satisfied 
EFNS/PNS clinical criteria.19 All of the CIDP misdiagnosis 
fell in the atypical CIDP group suggesting clinical criteria 
specificity of 80% (12/59 false positive). In addition, 15% 
of misdiagnosed patients satisfied EFNS/PNS electrodiag-
nostic criteria suggesting specificity of the electrodiagnostic 
criteria to be 93% (4/59 false positive).
While both CIDP and TTR-FAP can have autonomic 
involvement, these are milder in CIDP. For example, promi-
nent sphincter dysfunction excludes CIDP according to the 
EFNS/PNS 2010 criteria.3 In addition, certain features can 
help differentiate the two clinically. An echocardiogram or 
cardiac magnetic resonance imaging can be useful to iden-
tify evidence of an infiltrative cardiomyopathy, common in 
TTR-FAP and absent in CIDP. More recently, 99mTech-
netium-pyrophosphate imaging (Tc-PYP) is thought to be 
more sensitive to detect amyloid deposits than other car-
diac imaging modalities. In a study of 45 subjects (12 im-
munoglobulin light-chain amyloidosis [AL], 16 ATTR wild 
type, and 17 ATTR mutants), Tc-PYP cardiac imaging dis-
tinguished AL from ATTR cardiac amyloidosis.20 Patients 
can have elevated CSF protein which can be supportive of 
the diagnosis of CIDP, however TTR-FAP rarely has an el-
evated CSF protein. In our case, the CSF protein (73) was > 
60 mg/dl but many clinicians would consider this level ex-
pected for her age of 75. Lastly, 70%-90% of patients with 
CIDP respond to one or more of the standard therapies, 
which include corticosteroids, IVIG or plasma exchange.21 
Therefore, lack of treatment response should prompt re-
evaluation of the diagnosis.
Recently, Lozeron and colleagues (2018) identified 
clinical features that could predict demyelinating TTR-
FAP.22 In their cohort, 13 of 84 patients (15%) of French 
ancestry had late-onset demyelinating TTR-FAP. They 
identified several suggestive features. Our patient had some 
of these features including dysautonomia, small fiber sen-
sory loss above the wrists, and upper extremity weakness. 
Notably, our patient demonstrated sensory ataxia and did 
not have significant neuropathic pain, which differed from 
what was found in their demyelinating TTR-FAP cohort.22 
Our patient was found to have T60A mutation. This 
mutation is thought to have originated in northwestern Ire-
land and has now become prevalent in the United States, 
which it is referred to as Appalachian amyloidosis.23 It is 
estimated only 1% of patients worldwide with FAP have 
this mutation. A prospective study of sixty patients with the 
T60A mutation showed that a family history of amyloido-
sis was only present in 37%, median age of symptom onset 
was 63 years old, and the most common presenting symp-
tom was cardiac.24 Likewise, cardiomyopathy is nearly twice 
as common in patients with T60A mutation as compared 
patients with V30M mutation, the most common mutation 
worldwide.23,25 These studies have also demonstrated a link 
between prevalent cardiac involvement with shorter mean 
survival. Additionally, non-V30M patients as compared to 
V30M group have a worse 5-year survival after orthotropic 
liver transplant. Even after liver transplant, progression of 
disease has been found to occur, which is thought to be due 
to wild-type TTR deposition onto existing pathologic amy-
loid deposits. Thus, the need for alternative therapies ex-
its. Currently there are two TTR stabilizing drugs, tafami-
dis and diflunisal, and recently approved disease modifying 
drugs, inotersen and patisiran.12-15
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Conclusion
Late-onset proximal and distal weakness, with or 
without autonomic features, that is refractory to adequate 
first line therapy for CIDP, despite negative family history 
should raise clinical suspicion for FAP.
Corresponding Author: Amanda J. Thuringer, DO, 
athuringer@kumc.edu 
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